Full coverage view across outlets, lean, source quality, and framing. Compare framing without algorithmic ranking.
Appeals court blocks FDA rule that allows women to obtain abortion drugs by mail
A federal appeals court temporarily reinstated a nationwide requirement that abortion pills be obtained in person, undermining access to the method of abortion that has only grown more widespread since the US Supreme Court overturned Roe v. Wade. Friday’s ruling from the 5th US Circuit Court of Appeals is a major victory in the anti-abortion movement’s war against medication abortion, which now accounts for roughly two-thirds of all abortions in the United States. The ruling stems from a lawsuit filed by Louisiana last year against the US Food and Drug Administration, after President Donald Trump’s administration refused to act on calls to reinstate the in-person dispensing requirement for abortion pills through the regulatory process. The opinion was written by Trump-appointed Circuit Judge Kyle Duncan, joined by Circuit Judges Leslie Southwick and Kurt Engelhardt, who were appointed by Presidents George W. Bush and Trump, respectively. Referring to Louisiana abortion prohibitions, they wrote that the current federal regulations create “an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law.” Mifepristone manufacturer Danco Laboratories has asked the 5th Circuit to put its ruling on hold for seven days so it can appeal.
Federal Court Blocks Mailing of Abortion Pill Mifepristone. Here’s What to Know
A federal appeals court on Friday banned the mailing of the popular prescription abortion drug mifepristone, dealing a major blow to reproductive rights across the United States. The Fifth Circuit's unanimous ruling temporarily reinstated an in-person dispensing requirement, blocking a 2023 Food and Drug Administration (FDA) policy that allowed the drug to be prescribed via telehealth and delivered by mail. State attorneys argued that the mailing process subverted state bans on abortion and that it should be prescribed only in person or at clinics. "The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law," wrote Circuit Judge Kyle Duncan, of the New Orleans-based court.The ban will be challenged at the Supreme Court In response, Danco Laboratories, a manufacturer of the pill, asked the Supreme Court on Saturday to reinstate mail access to the drug, marking the potential for one of the biggest Supreme Court decisions on abortion since Dobbs v. Jackson Women’s Health Organization, which reversed the constitutional right to abortion, returning authority on the issue to state governments. Since the overturning of Roe v. Wade, around one in four abortions occur via telehealth appointments. Should
Abortion pill maker asks US supreme court to halt ban on mail-order access
A manufacturer of the abortion pill mifepristone, Danco Laboratories, filed an emergency appeal to the US supreme court on Saturday asking it to halt a court decision that would require an in‑person exam before the medication can be prescribed.The request came hours after the fifth US circuit court of appeals temporarily reinstated the requirement blocking telemedicine health providers from prescribing to patients by mail in response to a challenge from Louisiana.In an emergency filing on 2 May, the mifepristone maker asked the court to immediately pause the lower court’s ruling limiting access.In the filing, Danco said the circuit court’s ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions”, and would force Danco, providers, patients and pharmacies “all to guess at what is allowed and what is not”.Danco warned that the ruling would cause “chaos”.Louisiana argues that allowing the drug to be dispensed through the mail ignores the threat of complications from mifepristone, such as sepsis and hemorrhaging, and that delivery by mail allows women to get around abortion bans.In its ruling, the three-judge circuit court said it agreed with Louisiana that the looser rule “facilitates nearly 1,000 illegal abortions in Louisiana per month”. The pill is currently used
Supreme Court asked to restore access to mail-order abortion pill mifepristone
A pharmaceutical company that produces mifepristone asked the Supreme Court on Saturday to lift a lower court's ruling prohibiting health providers from dispensing the abortion pill by mail.In an emergency application filed Saturday, Danco Laboratories argued that Friday's ruling from the 5th U.S. Circuit Court of Appeals "causes immediate confusion and dramatic upheaval for manufacturers, distributors, providers, pharmacies, and patients around the country.""The resulting chaos for patients, providers, pharmacies, and the drug-regulatory system is a quintessential irreparable harm that underscores the need for emergency relief from this Court," lawyers for the company wrote in their filing. In this April 13, 2023, file photo, packages of Mifepristone tablets are displayed at a family planning clinic, in Rockville, Md.Anna Moneymaker/Getty Images, FILEThe lower court's order takes effect immediately and temporarily blocks 2023 Food and Drug Administration guidelines from the Biden administration that had eased access to the pill, citing an ongoing safety review by the Trump administration. The stay is in place as litigation continues.The application comes two years after the justices unanimously rejected a similar legal challenge to mifepristone, concluding that the doctors and anti-abortion groups who sued over the drug did not have standing.In their application on Saturday, lawyers for
What to know about federal court ruling blocking mailing of widely used abortion pill
In the biggest jolt to abortion policy in the U.S. since the overturning of Roe v. Wade, a federal appeals court has restricted access to one of the most common ways to end early pregnancies, by blocking the mailing of mifepristone prescriptions. The unanimous ruling Friday from the New Orleans-based 5th U.S. Circuit Court of Appeals marks a substantial victory for abortion opponents seeking to stem the flow of abortion pills prescribed online that they view as subverting state bans on the procedure. READ MORE: Court restricts abortion access across U.S. by blocking the mailing of mifepristone The ruling, which is expected to be appealed to the U.S. Supreme Court, requires that mifepristone be distributed only in person and at clinics, overruling regulations set by the federal Food and Drug Administration. Here's what to know. Impact extends beyond states with abortion bans Frustrated with a lack of federal action against medicated abortions, Louisiana Attorney General Liz Murrill sued the FDA last month, saying its regulations undermined the state's ban on abortions at all stages of pregnancy. "The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law,"
Abortion pill fight heads to Supreme Court as manufacturer warns of ‘chaos’ after ruling
NEWYou can now listen to Fox News articles! The legal battle over abortion pills escalated to the Supreme Court on Saturday, as the manufacturer of mifepristone filed an emergency request warning a lower court ruling is already causing "immediate confusion and upheaval" across the country.Danco Laboratories is asking the high court to quickly block a 5th U.S. Circuit Court of Appeals decision that blocked mail-order access and reinstated in-person requirements for the drug, arguing the ruling is disrupting access and creating nationwide uncertainty about legality.The ruling directly affects the distribution of mifepristone, Danco’s primary product.Mifepristone is one of two drugs commonly used in medication abortions.The application was directed to Justice Samuel Alito, who handles emergency matters from the 5th Circuit and can either act on his own or refer the request to the full court. The Supreme Court could act at any time.ABORTION PILL MIFEPRISTONE SPARKS NEW PRO-LIFE DEBATE AS SOME DOCTORS STRESS SAFETY CONCERNS Boxes of mifepristone, a pill used for medical abortions. (Evelyn Hockstein/Reuters, File)In its filing, Danco warned the appeals court’s order is already creating "chaos" in real-world medical settings."The panel’s ruling injects immediate confusion and upheaval into highly time-sensitive medical decisions," the company wrote, adding it
Supreme Court asked to pause ruling blocking telehealth and mail access to abortion pills
Danco Laboratories, one of the makers of the abortion pill mifepristone, asked the Supreme Court on Saturday to block a lower court ruling that imposed a nationwide requirement for the medication to be dispensed in person.In its filing, the drugmaker also asked the high court to grant an immediate pause of the lower court’s ruling while the Supreme Court considers the appeal.“Danco has been free to rely on the procedures set by FDA to distribute its product. The Fifth Circuit’s decision immediately ends that. A stay should issue to prevent the disruption and confusion that will result if the decision below were to remain operative,” lawyers for the company wrote in their filing.02:05The 5th Circuit U.S. Court of Appeals on Friday night granted the state of Louisiana’s request to reinstate an old requirement for abortion pills to be dispensed in person. That ruling was a win for anti-abortion activists because it bans the distribution of abortion pills via telehealth or mail.Distributing mifepristone by mail has been a key way for women who live in states with abortion bans to access abortion care since the Supreme Court overturned Roe v. Wade in 2022.In a statement, Planned Parenthood Action Fund President and
Supreme Court asked to keep abortion drug mifepristone available by mail
May 2, 2026Updated May 3, 2026, 1:10 p.m. ETWASHINGTON – Two years after the Supreme Court tossed out a challenge to the widely used abortion drug mifepristone, the justices must again decide whether access should be restricted.In emergency appeals filed May 2, drug makers Danco Laboratories and GenBioPro asked the court to immediately pause a lower court ruling limiting access.“The Supreme Court must reject this unfounded and baseless attack on an essential medication," GenBioPro CEO Evan Masingill said in a statement.The conservative 5th U.S. Circuit Court of Appeals on May 1 temporarily reinstated a Food and Drug Administration requirement that doctors prescribe the drug only after an in-person exam. The three-judge panel did so in response to a challenge from Louisiana to the elimination of that requirement by the Biden administration.'Nearly 1,000 illegal abortions' per monthLouisiana argues that allowing the drug to be dispensed through the mail ignores the threat of complications from mifepristone, such as sepsis and hemorrhaging. The state also says mailed delivery of the drug allows women to get around abortion bans.The appeals court agreed that the looser rule “facilitates nearly 1,000 illegal abortions in Louisiana per month.”Multiple Republican-led states are trying to make it harder for
+1 more
No coverage from this perspective yet.
Pro users see canonical claims across the cluster and which outlets reported each one.
Learn moreFirst seen
May 1, 2026
Latest
May 2, 2026
Outlets
9
Diversity
100/100
© 2026 Vistoa. All rights reserved.
Limited excerpts, attribution, analysis, and outbound publisher links remain core product boundaries.
